Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardian Pharmacy ServicesGRDN +1.21%39 3-Year EBITDA Growth Rate is 10.80% as of Jun. 2026, which is 24% above its 10-year median of 8.70. GuruFocus rates GRDN with a GF Score™ of 39/100. Among 526 Healthcare Providers & Services companies, Guardian Pharmacy Services ranks better than 51.14% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Guardian Pharmacy Services was 11.30% per year. The lowest was 6.20% per year. And the median was 8.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Guardian Pharmacy Services 3-Year EBITDA Growth Rate Related Terms
GRDN vs MD, ADUS, AVAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Guardian Pharmacy Services's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardian Pharmacy Services 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Guardian Pharmacy Services's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Guardian Pharmacy Services's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.80% mean?
Guardian Pharmacy Services (GRDN) has a 3-Year EBITDA Growth Rate of 10.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Guardian Pharmacy Services and its competitors. This is 24% above median its historical median of 8.70. Over the past decade, Guardian Pharmacy Services' 3-Year EBITDA Growth Rate has ranged from 6.20 to 11.30. According to the industry distribution chart, Guardian Pharmacy Services ranks #257 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 48.9%.
Is Guardian Pharmacy Services' 3-Year EBITDA Growth Rate too high?
Guardian Pharmacy Services' current 3-Year EBITDA Growth Rate of 10.80% is 24% above median its 10-year median of 8.70. Over the past 10 years, this metric has ranged from a low of 6.20 to a high of 11.30. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Guardian Pharmacy Services' value of 10.80% is 5.9% above this industry median. Based on the distribution chart, Guardian Pharmacy Services ranks #257 out of 526 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Guardian Pharmacy Services has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Guardian Pharmacy Services' 3-Year EBITDA Growth Rate compare to MD and ADUS?
According to the Healthcare Providers & Services industry distribution chart, Guardian Pharmacy Services ranks #257 out of 526 companies for 3-Year EBITDA Growth Rate. This puts Guardian Pharmacy Services in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Guardian Pharmacy Services' value of 10.80% is 5.9% above this benchmark. Historically, Guardian Pharmacy Services' own 3-Year EBITDA Growth Rate has ranged from 6.20 to 11.30 over the past decade. While the company's 10-year median is 8.70 vs. the industry median of 10.20, Guardian Pharmacy Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guardian Pharmacy Services's current 3-Year EBITDA Growth Rate of 10.80% is 5.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Guardian Pharmacy Services and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardian Pharmacy Services's current 3-Year EBITDA Growth Rate is 10.80%, which is 24% above median its own 10-year median of 8.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardian Pharmacy Services stock overvalued right now?
Guardian Pharmacy Services (GRDN) has a current 3-Year EBITDA Growth Rate of 10.80%. The current 3-Year EBITDA Growth Rate is 10.80%, which is 24% above median its 10-year median of 8.70 and 5.9% above the Healthcare Providers & Services industry median of 10.20. Guardian Pharmacy Services' overall GF Score™ is 39/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Guardian Pharmacy Services (GRDN), the current 3-Year EBITDA Growth Rate is 10.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
39GF Score
Get the complete analysis for GRDN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRDN has been successfully added to your 
